This is a competing renewal application for a P60 Center that was formed in 1987 with the theme of, improving treatment of addiction. At that point the critical mass of investigators with R01s from NIDA, NIAAA and even NIMH had become so large that a center structure with a large core to provide the infrastructure needed to coordinate a large number of clinical research projects was needed. After one term it was changed from a P50 mechanism to a P60 mechanism at the suggestion of then NIDA Director, Alan Leshner, because of the diversity of projects, education programs and dissemination programs conducted in the Center. It was felt by Dr. Leshner that the large size and diverse nature of activities of this Center required the flexibility of a P60 comprehensive research center. Thus, a major portion of the productivity of this Center is in its multiple educational programs for medical students, residents, undergraduates, postdoctoral fellows, minorities, community clinicians, probation officers, judges and legislators. As expected of a P60, we have always had a basic research component with an eye toward translation of findings from the lab to the clinic through clinical trials and the translation of technology from clinical trials to the community practitioner. Recent activities are described in the Progress Report. Our ultimate goal is to have an impact on clinical practice in the management of addictive disorders. Thus the over-arching theme of this Center has always been research that results in improvement of treatment of substance abuse. Admittedly, this is not a highly specific theme demanded of a P50 focused center, but rather an integrative theme in keeping with a P60 comprehensive center. Each of the four previous reviews since 1987 have commented on the broadness of this theme, but all concluded that it was appropriate for a P60 center of this kind. In this competing renewal application we present the accomplishments of the past five years, detail the operations of the Cores and propose four new projects: Proj. 1 is a basic project addressing opiate addiction by a study of Mu Opiate Receptor Interacting Proteins using well characterized samples obtained from patients in our clinical trials and NIH sources;.Proj. 2 addresses the growing problem of prescription opioid abuse by conducting a longitudinal study of primary care patients beginning treatment with opioids for chronic pain;Proj. 3 &4 address cocaine addiction and the spread of HIV. Proj. 3 proposes the study of an adaptive treatment for cocaine dependence;and Proj. 4 is a clinical trial of modafinil in women involved in trading sex for cocaine. Two proposed pilot projects focus on brain imaging of craving in marijuana and nicotine dependent patients using strategies developed in our prior studies of cocaine and opiate addiction. CENTER CHARACTERISTICS

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Comprehensive Center (P60)
Project #
3P60DA005186-23S2
Application #
7878891
Study Section
Special Emphasis Panel (ZDA1-RXL-E (29))
Program Officer
Aklin, Will
Project Start
1992-09-30
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
23
Fiscal Year
2009
Total Cost
$128,048
Indirect Cost
Name
University of Pennsylvania
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Franklin, Teresa R; Jagannathan, Kanchana; Hager, Nathan et al. (2018) Brain substrates of early (4h) cigarette abstinence: Identification of treatment targets. Drug Alcohol Depend 182:78-85
Wetherill, Reagan R; Jagannathan, Kanchana; Hager, Nathan et al. (2016) Influence of menstrual cycle phase on resting-state functional connectivity in naturally cycling, cigarette-dependent women. Biol Sex Differ 7:24
Woody, George E; Krupitsky, Evgeny; Zvartau, Edwin (2016) Antagonist Models for Relapse Prevention and Reducing HIV Risk. J Neuroimmune Pharmacol 11:401-7
Van Horn, Deborah H A; Drapkin, Michelle; Lynch, Kevin G et al. (2015) Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatment. Addict Res Theory 23:391-403
Franklin, Teresa R; Jagannathan, Kanchana; Wetherill, Reagan R et al. (2015) Influence of menstrual cycle phase on neural and craving responses to appetitive smoking cues in naturally cycling females. Nicotine Tob Res 17:390-7
Kampman, Kyle M; Lynch, Kevin G; Pettinati, Helen M et al. (2015) A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend 155:105-10
Goldman, Marina; Ehrman, Ronald N; Suh, Jesse J et al. (2015) Brief report: ""spiders-No, puppies-Go"", introducing a novel Go NoGo task tested in inner city adolescents at risk for poor impulse control. J Adolesc 38:45-8
McKay, James R; Drapkin, Michelle L; Van Horn, Deborah H A et al. (2015) Effect of patient choice in an adaptive sequential randomization trial of treatment for alcohol and cocaine dependence. J Consult Clin Psychol 83:1021-32
Clarke, T-K; Crist, R C; Ang, A et al. (2014) Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14:303-8
Clarke, Toni-Kim; Weiss, Amy R D; Ferarro, Thomas N et al. (2014) The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. Ann Hum Genet 78:33-9

Showing the most recent 10 out of 111 publications